iZafe Group AB (publ) (IZAFE-B.ST)
SEK 0.26
(3.6%)
SEK 0.26
(3.6%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.26 Million SEK | -21.12% |
| 2022 | 11.74 Million SEK | 52.55% |
| 2021 | 7.69 Million SEK | 36.89% |
| 2020 | 5.62 Million SEK | -83.87% |
| 2019 | 34.85 Million SEK | 4.17% |
| 2018 | 33.46 Million SEK | 1224.22% |
| 2017 | 2.52 Million SEK | -5.55% |
| 2016 | 2.67 Million SEK | -27.63% |
| 2015 | 3.69 Million SEK | -39.01% |
| 2014 | 6.06 Million SEK | 11.88% |
| 2013 | 5.41 Million SEK | 4.52% |
| 2012 | 5.18 Million SEK | 993.6% |
| 2011 | 474.05 Thousand SEK | -40.66% |
| 2010 | 798.87 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 9.56 Million SEK | 3.3% |
| 2024 Q2 | 7.51 Million SEK | -21.41% |
| 2024 Q3 | 11.33 Million SEK | 50.78% |
| 2023 Q2 | 10.15 Million SEK | 2.45% |
| 2023 Q4 | 9.26 Million SEK | 5.32% |
| 2023 Q3 | 8.79 Million SEK | -13.44% |
| 2023 FY | 9.26 Million SEK | -21.12% |
| 2023 Q1 | 9.91 Million SEK | -15.55% |
| 2022 Q3 | 7.55 Million SEK | 18.96% |
| 2022 FY | 11.74 Million SEK | 52.55% |
| 2022 Q1 | 7.99 Million SEK | 3.82% |
| 2022 Q2 | 6.34 Million SEK | -20.54% |
| 2022 Q4 | 11.74 Million SEK | 55.43% |
| 2021 Q1 | 19.77 Million SEK | 251.76% |
| 2021 FY | 7.69 Million SEK | 36.89% |
| 2021 Q4 | 7.69 Million SEK | -76.01% |
| 2021 Q3 | 32.08 Million SEK | 33.6% |
| 2021 Q2 | 24.01 Million SEK | 21.44% |
| 2020 Q4 | 5.62 Million SEK | 12.8% |
| 2020 Q1 | 22.37 Million SEK | -35.8% |
| 2020 Q2 | 25.87 Million SEK | 15.6% |
| 2020 Q3 | 4.98 Million SEK | -80.73% |
| 2020 FY | 5.62 Million SEK | -83.87% |
| 2019 Q3 | 26.23 Million SEK | -19.07% |
| 2019 FY | 34.85 Million SEK | 4.17% |
| 2019 Q4 | 34.85 Million SEK | 32.86% |
| 2019 Q1 | 34.21 Million SEK | 2.24% |
| 2019 Q2 | 32.42 Million SEK | -5.24% |
| 2018 Q4 | 33.46 Million SEK | 22.66% |
| 2018 FY | 33.46 Million SEK | 1224.22% |
| 2018 Q2 | 12.9 Million SEK | 225.28% |
| 2018 Q3 | 27.28 Million SEK | 111.37% |
| 2018 Q1 | 3.96 Million SEK | 57.02% |
| 2017 FY | 2.52 Million SEK | -5.55% |
| 2017 Q1 | 2.04 Million SEK | -23.73% |
| 2017 Q2 | 1.83 Million SEK | -9.89% |
| 2017 Q3 | 1.28 Million SEK | -30.19% |
| 2017 Q4 | 2.52 Million SEK | 96.84% |
| 2016 Q2 | 7.26 Million SEK | 0.0% |
| 2016 Q4 | 2.67 Million SEK | 0.0% |
| 2016 FY | 2.67 Million SEK | -27.63% |
| 2016 Q1 | - SEK | -100.0% |
| 2015 Q1 | 4.33 Million SEK | -28.46% |
| 2015 FY | 3.69 Million SEK | -39.01% |
| 2015 Q4 | 3.69 Million SEK | 0.0% |
| 2015 Q3 | 3.69 Million SEK | 80.42% |
| 2015 Q2 | 2.04 Million SEK | -52.75% |
| 2014 Q3 | 5.96 Million SEK | 2.12% |
| 2014 Q1 | 6.53 Million SEK | 20.67% |
| 2014 Q2 | 5.84 Million SEK | -10.67% |
| 2014 FY | 6.06 Million SEK | 11.88% |
| 2014 Q4 | 6.06 Million SEK | 1.64% |
| 2013 Q1 | 5.18 Million SEK | -0.01% |
| 2013 Q4 | 5.41 Million SEK | -5.76% |
| 2013 Q3 | 5.74 Million SEK | 4.84% |
| 2013 Q2 | 5.48 Million SEK | 5.79% |
| 2013 FY | 5.41 Million SEK | 4.52% |
| 2012 FY | 5.18 Million SEK | 993.6% |
| 2012 Q3 | 235.99 Thousand SEK | 0.0% |
| 2012 Q4 | 5.18 Million SEK | 2096.76% |
| 2011 FY | 474.05 Thousand SEK | -40.66% |
| 2010 FY | 798.87 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AddLife AB (publ) | 7.78 Billion SEK | 99.881% |
| Biotage AB (publ) | 1.27 Billion SEK | 99.273% |
| Bonesupport Holding AB (publ) | 143.63 Million SEK | 93.553% |
| Doxa AB (publ) | 280.8 Million SEK | 96.702% |
| Elekta AB (publ) | 21.61 Billion SEK | 99.957% |
| Ortivus AB (publ) | 55.4 Million SEK | 83.284% |
| Ortivus AB (publ) | 55.4 Million SEK | 83.284% |
| Q-linea AB (publ) | 42.34 Million SEK | 78.127% |
| S2Medical AB (publ) | 19.74 Million SEK | 53.108% |
| Synsam AB (publ) | 5.52 Billion SEK | 99.832% |